GlassScriptPhysician profile
Luisa A Duran
NPI 1548437940
$774.76
in general payments reported to CMS, 2019-2025
10 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.44 · 2023: $88.52 · 2024: $156 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Education: $11.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.65 |
| Education | $11.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $182.95 | 2025 | Nucala |
| Dexcom, INC. | $163.88 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.91 | 2024 | Jardiance |
| Amgen INC. | $110.46 | 2023-2025 | Evenity, Prolia |
| Medtronic, INC. | $58.34 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $28.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.71 | 2025 | |
| Sequel Med Tech, LLC | $25.73 | 2025 | Twiist |
| Ibsa Pharma INC. | $22.44 | 2019 | |
| Abbott Laboratories | $20.06 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisa Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.